Bone matrix properties in adults with osteogenesis imperfecta are not adversely affected by setrusumab—a sclerostin neutralizing antibody
Authors' conclusion
We conclude that SclAb treatment leads to increased bone mass while not adversely affecting bone matrix properties in individuals with OI.
Study context
- Population
- Adults with type I, III and IV osteogenesis imperfecta (OI) and controls without metabolic bone disease
- Comparison
- Setrusumab-treated OI vs untreated OI vs controls
- Outcome
- Bone matrix material properties
- Follow-up
- 6 mo of setrusumab
Methodological detailstetracycline-labeled trans iliac biopsies, substudy of the Phase 2b ASTEROID trial
- Tetracycline-labeled trans iliac biopsies
- Substudy of the Phase 2b ASTEROID trial
Main finding
As reported in the abstract
- No difference in collagen orientation between the groups
- OI groups had greater mean mineralization, greater relative mineral content and lower crystallinity than control, not altered by SclAb treatment
- Lower modulus and hardness in inter-label bone of OI-SclAb vs OI
Original publication
Bone matrix properties in adults with osteogenesis imperfecta are not adversely affected by setrusumab—a sclerostin neutralizing antibody. J Bone Miner Res. Published 10 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →